



Neurotech secures digital marketing partner as part of new go-to-market strategy

Perth, Australia & Malta – 15 February 2019 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) has chosen ANCHOVY. Plc (MSE: ANC) as its digital lead generation partner. ANCHOVY. will support Neurotech’s new strategic direction which focuses on delivering *Mente* through a subscription-based go-to-market model focused exclusively on enabling clinics to offer *Mente* to their patients.

ANCHOVY. was established in 2013 with the aim of building one of Europe’s premier digital lead-generation agencies. It was recently chosen by Medis, a leading global provider of software to clinicians, technician and researchers, as its brand positioning partner. Its clients also include Lufthansa, McDonald’s, Foster Clark, Air Arabia, InterContinental Hotels and Al Tayer Group. The company operates out of Malta with a presence in Amsterdam and Dubai.

Neurotech CEO and Managing Director Peter Griffiths said: “We are very pleased to have ANCHOVY. as our digital lead generation partner. As we focus on developing a network of clinics and clinicians who will use *Mente* as part of a treatment plan for their patients, generating leads and developing a strong and visible web presence will be critical to the success of our business. ANCHOVY. understands our approach and thinking, and I look forward to building momentum in the partnership as we prepare to launch our pilot in March. The ANCHOVY. team add deep domain experience to our company which is critical in scaling to meet our goals over the months and quarters ahead.”

ANCHOVY. Plc co-founder and executive director Zak Borg said: “We are excited to work with Neurotech and support their digital lead generation and marketing efforts. *Mente* is an innovative product in the marketplace and we are honored that Neurotech have chosen us to lead this part of its new strategy.”

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device *Mente* and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Neurotech International Ltd

ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420